AZ to pull bleeding reversal agent after FDA flags risk imbalance.

AstraZeneca is set to withdraw its bleeding reversal agent from the market following concerns raised by the FDA regarding a risk imbalance. While not an acquisition, this regulatory action could influence AZ's strategic decisions regarding its portfolio.